Sanner Group COO Frank Bamberg Appointed to Lead Operations
Sanner Group appoints Frank Bamberg as COO to grow pharmaceutical packaging and strengthen medical device CDMO manufacturing.


Sanner Group has appointed Frank Bamberg as Chief Operating Officer (COO), effective September 15, 2026. Bamberg brings more than 20 years of international experience in regulated manufacturing, with expertise spanning medical devices, combination products, and operations across the product lifecycle from research and development to commercial manufacturing.
In his new role, Bamberg will bring operational leadership experience focused on building scalable manufacturing operations and strengthening manufacturing readiness. His background includes managing activities across product development and commercial production in highly regulated healthcare environments.
“With his extensive experience in international manufacturing operations across the pharma, biotech, and medtech industries, Frank Bamberg is an excellent fit for Sanner,” says Stefan Verheyden, CEO of the Sanner Group. “He will play an important role in growing our pharmaceutical packaging production while also strengthening manufacturing readiness for our growing medical device CDMO business.”
Frank Bamberg adds: “I am very much looking forward to further developing Sanner’s international production network and ensuring consistently high quality across all locations. I see enormous potential and will be happy to help translate that potential into sustainable growth.”
Before joining Sanner Group, Bamberg served as Head of Primary Packaging and Medical Devices Product Care at CSL Behring. He previously held senior positions at Hoffmann-La Roche and Schott, working across Switzerland and the United States.
Bamberg succeeds Heino Lennartz, who has served as interim COO since autumn 2025. Following the appointment, Lennartz will return full-time to his position as Chairman of the Sanner Group. The leadership change comes as Sanner continues its work in healthcare packaging and medical device contract development and manufacturing.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
CERVAVAC WHO Prequalification Secured by Serum Institute

BIX 2026 Counts Down to Opening with Post-GLP-1 Session on the Next Obesity Treatment Market

Discussion